A Phase III, Double Blind, Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Diseases and Conditions Researched

Colon

What is the purpose of this trial?

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.


Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Southwest Oncology Group (SWOG)
Dates:
Last Updated:
Study HIC#: 1402013375